Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.
Checked against the public recordLast updated Sep 22, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Milton S. Hershey Medical Center
- Interventions being studied
- Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel; Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced non-squamous NSCLC * No prior chemotherapy for advanced disease * ECOG performance status 0 or 1 * Measurable disease * Life expectancy \> 3 months * Normal bone marrow, renal and hepatic function * Ability to take oral medications * Willingness to sign informed consent Exclusion Criteria: * History of brain metastasis * Evidence of thromboembolic phenomenon and treatment with anticoagulants * Pregnancy * Uncontrolled inter-current illness * Prior therapy with Paclitaxel
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Penn State College of Medicine, Penn State Milton S. Hershey Medical CenterHershey, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2016. Always confirm current availability with the study team.